Table 1.
Altered cell-free circulating miRNAs in various cancer types (selection)
| MicroRNA | Type of deregulation | Possible application |
|---|---|---|
| let-7a | Decrease in gastric cancer | Discriminate gastric cancer from healthy controls |
| let-7f | Decrease in NSCLC | Associated with overall survival in NSCLC |
| miR-1 | Decrease in NSCLC | Associated with overall survival in NSCLC |
| miR-10b | Increase in breast cancer | Associated with metastases in breast cancer |
| miR-17 | Increase in gastric cancer | Discriminate gastric cancer from healthy controls |
| miRs-17+106a | Increase in gastric cancer | Discriminate gastric cancer from healthy controls |
| miR-17-3p | Increase in CRC | Discriminate CRC from healthy controls |
| miR-17-5p | Increase in gastric cancer | Discriminate gastric cancer from healthy control |
| miR-20b | Decrease in NSCLC | Associated with advanced stages and lymph node metastases in NSCLC |
| miR-21 | Increase in CLL harbouring 17p deletion | Associated with overall survival in CLL |
| miRs-21+126+210+486+5p | Deregulate in NSCLC | Discriminate stage/NSCLC from healthy controls |
| miRs 21+155+196a+210 | Increase in pancreatic adenocarcinoma | Discriminate pancreatic adenocarcinoma from healthy controls |
| miR-29a | Increase in CRC | Discriminate CRC from healthy controls |
| miR-29b, miR-29c | Decrease in CLL harbouring 17p deletion | Associated with progression in CLL |
| miR-30d | Increase in NSCLC | Associated with overall survival inNSCLC |
| miR-30e-3p | Decrease in NSCLC | Associated with short disease free survival in NSCLC |
| miR-34a | Increase in breast cancer | Discriminate advanced stages from early stages in breast cancer |
| miR-92, miR-92a | Increase in CRC | Discriminate CRC from Gastric Cancer, IBD, and healthy controls |
| miR-106a | Increase in gastric cancer | Discriminate gastric cancer from healthy controls |
| miR-106b | Increase in gastric cancer | Discriminate gastric cancer from healthy controls |
| miR-144 | Decrease in CN-AML | Associated with adverse prognostic marker FLT3-ITD in CN-AML |
| miR-181a | Increase in CLL harboring trisomy 12 | Associated with progression in CLL |
| miR-195 | Increase in breast cancer | Discriminate breast cancer from other cancers and from healthy controls |
| miR-200a, miR-200b | Increase in pancreatic cancer | Discriminate pancreatic cancer from healthy controls |
| miR-451 | Increase in breast cancer | Associated with malignancy in breast cancermiR |
| miR-486 | Increase in NSCLC | Associated with overall survival in NSCLC |
| miR-499 | Decrease in NSCLC | Associated with overall survival in NSCLC |